What are the responsibilities and job description for the Scientist, Analytical Development position at MBX Biosciences, Inc.?
Position Summary
The Scientist, Analytical Development will support the development, qualification, transfer, and lifecycle management of physicochemical and impurity analytical methods for peptide therapeutic programs from early clinical to commercial development. This role will focus on the design and execution of chromatographic and electrophoretic methods (LC, LC-MS, and CE) to enable product characterization, release, stability testing, and comparability assessments. Reporting into our Associate Director of Analytical Development, this individual will work collaboratively with other MBX functions and external CDMO partners to ensure phase-appropriate, scientifically sound, and compliant physicochemical and impurity methods are implemented across the portfolio.
Key Responsibilities
This role operates in an onsite work model, with an expectation of four to five on-site days per week at the Burlington site. The position also requires periodic travel aligned with business needs, including participation in Together Weeks (once a quarter) and functional or company meetings, as directed by the Company.
Company Overview
MBX Biosciences, Inc. (NASDAQ: MBX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The Company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow us on LinkedIn.
EEO Statement
MBX Biosciences is an Equal Opportunity Employer and is committed to treating all applicants fairly without discrimination. We welcome applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law.
The Scientist, Analytical Development will support the development, qualification, transfer, and lifecycle management of physicochemical and impurity analytical methods for peptide therapeutic programs from early clinical to commercial development. This role will focus on the design and execution of chromatographic and electrophoretic methods (LC, LC-MS, and CE) to enable product characterization, release, stability testing, and comparability assessments. Reporting into our Associate Director of Analytical Development, this individual will work collaboratively with other MBX functions and external CDMO partners to ensure phase-appropriate, scientifically sound, and compliant physicochemical and impurity methods are implemented across the portfolio.
Key Responsibilities
- Perform a range of routine and non-routine analyses of API and Drug Product for MBX’s peptide portfolio using various pharmaceutical analysis techniques.
- Perform hands-on laboratory work including method development, optimization, troubleshooting, and routine execution of chromatographic, mass spectrometry, and electrophoretic assays (e.g., RP-HPLC, SEC, IEX, CE-SDS, icIEF, LC-MS).
- Help build and maintain internal analytical capabilities for LC/MS/CE platforms, including instrument qualification, maintenance, and training of other staff.
- Provide technical support for analytical development activities at external CROs/CMOs.
- Collaborate cross-functionally with Discovery, Pre-Clinical, Quality, and Regulatory teams to ensure analytical support priorities are aligned with program needs.
- Co-author and review analytical method development, validation, and characterization sections of regulatory filings, including IND, INDa, IMPD, and NDA/BLA submissions.
- Support investigations for OOT/OOS analytical results.
- Stay current with evolving regulatory guidance, pharmacopeial standards, and best practices in chromatographic and mass spectrometry-based analytical development.
- Other responsibilities as assigned.
- Ph.D. in Analytical Chemistry, Pharmaceutical Sciences, or related discipline with 1 years, M.S. with 2 years, B.S. with 4 years of relevant industry experience.
- Strong expertise in chromatographic, mass spectrometric, and electrophoretic techniques (HPLC/UPLC, LC-MS, CE) including method development and qualification for peptide therapeutics or related modalities.
- Hands-on experience with mass spectrometry for peptide characterization (e.g., intact mass, peptide mapping, impurity identification) preferred.
- Familiarity with regulatory requirements and guidelines (ICH, FDA, EMA, JP) related to analytical method development, validation, and control strategies.
- Proven ability to interpret complex analytical data (e.g., chromatographic profiles, spectral data) and apply scientific judgment to development and troubleshooting.
- Experience supporting analytical activities at external partners (CROs/CMOs) and operating in cross-functional collaborations preferred.
- Excellent written and verbal communication skills, including experience authoring method development and qualification documentation.
- Strong organizational skills with the ability to manage multiple priorities in a fast-paced environment.
This role operates in an onsite work model, with an expectation of four to five on-site days per week at the Burlington site. The position also requires periodic travel aligned with business needs, including participation in Together Weeks (once a quarter) and functional or company meetings, as directed by the Company.
Company Overview
MBX Biosciences, Inc. (NASDAQ: MBX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The Company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow us on LinkedIn.
EEO Statement
MBX Biosciences is an Equal Opportunity Employer and is committed to treating all applicants fairly without discrimination. We welcome applications from all individuals, regardless of race, national origin, gender, age, physical characteristics, social origin, disability, union membership, religion, family status, pregnancy, sexual orientation, gender identity, gender expression or any unlawful criterion under applicable law.